-
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Wednesday, July 26, 2017 - 10:58am | 442Read More...Despite a strong quarter, analysts see a difficult road ahead for Eli Lilly And Co (NYSE: LLY). “Even though Eli Lilly's launch execution has been outstanding," Leerink Managing Director Seamus Fernandez said, "the ways for LLY investors to win in our view appear limited when...
-
Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar
Thursday, June 29, 2017 - 11:42am | 316Read More...After completing a sum-of-the-parts analysis, UBS analyst Marc Goodman still sees Mallinckrodt PLC (NYSE: MNK) as a strong risk/reward play. Goodman maintained his Buy rating and 12-month $70 price target. “The key overhang for the stock remains the sustainability of Acthar, particularly from...
-
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Thursday, April 6, 2017 - 1:45pm | 510Read More...Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) announced on Wednesday it has reached a settlement agreement with Hikma Pharmaceuticals Plc (ADR) (OTC: HKMPY) to resolve a patent litigation related to Xyrem oral solution that has been pending in the U.S. District Court for the...
-
Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?
Friday, November 25, 2016 - 12:09pm | 302Read More...Marc Goodman of UBS lowered his EPS estimates for Eli Lilly and Co (NYSE: LLY) after the company announced that its Alzheimer's drug solanezumab failed to slow the cognitive decline in patients. Goodman, who previously had modeled about $1.1 billion for 2020 solanezumab sales, has cut 2016 EPS...
-
Near-Term Headwinds And Long-Term Promise For Gilead Sciences
Wednesday, November 2, 2016 - 1:35pm | 200Read More...UBS says the focus on Gilead Sciences, Inc. (NASDAQ: GILD) is shifting to NASH amid weaker HCV sales. The brokerage maintains its Buy rating, as it remains encouraged by the top-line ' 4997 data in NASH and the company's plan to enter Phase 3 in the first quarter 2017 with combo studies...
-
Allergan Again A Core Holding At UBS
Wednesday, April 27, 2016 - 10:41am | 259Read More...Shares of Allergan plc Ordinary Shares (NYSE: AGN) are down 22 percent since March 28. UBS’ Marc Goodman maintained a Buy rating for the company, with a price target of $300. Potential Core Holding Analyst Marc Goodman mentioned that while Allergan has emerged as a larger company with...
-
UBS Suspends Coverage Of Valeant Over Lack of Transparency
Monday, March 21, 2016 - 9:05am | 104Read More...UBS’ Marc Goodman suspended coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX), citing lack of transparency in the company’s financials and uncertainty over the timeline of the visibility. Goodman believes that under these circumstances it is not practical to forecast the...
-
Some On Wall Street Still Back Valeant
Tuesday, March 15, 2016 - 11:51am | 558Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged 40 percent and touched a new 52-week low after the company reported a loss for its fourth quarter and slashed its outlook. The company cited incremental headwinds in Ophthalmology Rx, as well as the Commonwealth and Western Europe businesses...
-
Valeant's New-Old CEO: What To Know
Wednesday, March 2, 2016 - 3:33pm | 350Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Chief Executive Michael Pearson, who just got back from a two-month sick leave, has his job cut out. The Canadian pharma company is facing several issues including delayed filing of its 10-K, a potential earnings restatement, withdrawn 2016...
-
These Four Analysts Remain Bullish On Valeant
Thursday, October 22, 2015 - 10:36am | 756Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) collapsed to a new 52-week low of $88.50 on Wednesday before slightly rebounding but have still lost more than 50 percent over the past three months.. Citron Research published what it considered to be a "smoking gun" report on Wednesday which...
-
UBS On Bristol-Myers Squibb: 'We Like This Opportunity Right Here Right Now'
Tuesday, September 29, 2015 - 10:32am | 312Read More...Bristol-Myers Squibb Co (NYSE: BMY) shares are down 13 percent in the last three months, despite touching a 52-week high of $70.54 on July 14. UBS analyst Marc Goodman upgraded the rating on the company from Neutral to Buy, while raising the price target from $65 to $75. Bristol-Myers...
-
Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210
Monday, June 29, 2015 - 11:11am | 260Read More...In a report published Monday, UBS analyst Marc Goodman maintained a Buy rating on Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ), while raising the price target from $190 to $210. "We still expect that Xyrem sales should grow to ~$900M by 2015 and remain protected from generics at least...
-
UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies
Monday, June 1, 2015 - 9:38am | 382Read More...In a report published Sunday, UBS analyst Marc Goodman reviewed key data points from the American Society of Clinical Oncology (ASCO). AbbVie: Ph-III Helios Data 'Quite Strong' Goodman noted that AbbVie Inc (NYSE: ABBV)'s data for Helios Imbruvica combo in 2L CLL/SLL was "...
-
UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell
Friday, April 17, 2015 - 10:52am | 288Read More...UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) Thursday from Neutral to Sell and maintained a $36 price target. Analyst Marc Goodman noted that the stock had run up on expectations that the company may get acquired or do other deals. While Goodman expected more deals to come, the stock...
-
UBS Thinks AbbVie's Valuation Is 'Interesting'
Monday, February 2, 2015 - 12:18pm | 249Read More...UBS commented on AbbVie Inc (NYSE: ABBV) Friday and maintained a Buy rating with a $76 price target following the company’s Q4 earnings call. Analyst Marc Goodman felt that AbbVie’s management tends to be conservative in its guidance and there is “much more to go” when...
